Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest

被引:89
作者
Ahamad, A [1 ]
Stevens, CW [1 ]
Smythe, WR [1 ]
Liao, ZX [1 ]
Vaporciyan, AA [1 ]
Rice, D [1 ]
Walsh, G [1 ]
Guerrero, T [1 ]
Chang, J [1 ]
Bell, B [1 ]
Komaki, R [1 ]
Forster, KM [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Sect Thorac Mol Oncol,Dept Thorac & Cardiovasc Su, Houston, TX 77030 USA
关键词
mesothelioma; IMRT; radiotherapy;
D O I
10.1097/00130404-200311000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Malignant pleural mesothelioma often recurs locally in spite of aggressive resection by extrapleural pneumonectomy and conventional radiotherapy. This may be due to failure to recognize the extent of clinical target volume (CTV) or suboptimal dose delivery to a target that abuts the heart, esophagus, liver, lung, kidney, and spinal cord. We report how these geometric/dosimetric constraints were overcome by exploiting intensity-modulated radiotherapy in the first cohort patient. MATERIALS AND METHODS Twenty-eight patients who had undergone extrapleural pneumonectomy were treated with intensity-modulated radiotherapy. The CTV included the surgically violated inner chest wall, insertion of diaphragm, pleural reflections, and deep margin of the incision. CTV delineation was facilitated by intraoperative radio-opaque marking. Motion was assessed. CTV doses were 45-50 Gy with boosts taken to 60 Gy. RESULTS Despite the large, irregular CTV (median, 4151 cc; range, 2667-7286 cc), an average of 97% of the CTV was covered to the target dose (range, 92%-100%). Respiratory motion was minimal because of immobility of the prosthetic diaphragm. Normal tissue dose constraints were met. The commonest effects were nausea/vomiting (89%) and dyspnea (80%). Esophagitis. was absent (59% of patients) or mild (34% grade 1/2). At median follow-up of 9 months (range, 5-27 months), local control within the contoured target was 100%. One-year survival, disease-specific survival, and disease-free survival are 65%, 91%, and 88%, respectively. CONCLUSIONS Intensity-modulated radiotherapy after extrapleural pneumonectomy is tolerable and seems effective, at least at this early point. As local control improves, systemic metastases become more common, and it may be appropriate to add novel agents to further improve the therapeutic ratio.
引用
收藏
页码:476 / 484
页数:9
相关论文
共 37 条
[21]   Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences [J].
Pass, HI ;
Donington, JS ;
Wu, P ;
Rizzo, P ;
Nishimura, M ;
Kennedy, R ;
Carbone, M .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1998, 116 (05) :854-858
[22]   Surgically debulked malignant pleural mesothelioma: Results and prognostic factors [J].
Pass, HI ;
Kranda, K ;
Temeck, BK ;
Feuerstein, I ;
Steinberg, SM .
ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (03) :215-222
[23]  
Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093
[24]  
RUBIN P, 1993, CLIN ONCOLOGY MULTID, P72
[25]   DIFFUSE MALIGNANT MESOTHELIOMA OF THE PLEURA IN ONTARIO AND QUEBEC - A RETROSPECTIVE STUDY OF 332 PATIENTS [J].
RUFFIE, P ;
FELD, R ;
MINKIN, S ;
CORMIER, Y ;
BOUTANLAROZE, A ;
GINSBERG, R ;
AYOUB, J ;
SHEPHERD, FA ;
EVANS, WK ;
FIGUEREDO, A ;
PATER, JL ;
PRINGLE, JF ;
KREISMAN, H .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1157-1168
[26]  
RUSCH VW, 1991, J THORAC CARDIOV SUR, V102, P1
[27]   PLEURECTOMY/DECORTICATION AND ADJUVANT THERAPY FOR MALIGNANT MESOTHELIOMA [J].
RUSCH, VW .
CHEST, 1993, 103 (04) :S382-S384
[28]   Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically [J].
Rusch, VW ;
Venkatraman, ES .
ANNALS OF THORACIC SURGERY, 1999, 68 (05) :1799-1804
[29]   A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma [J].
Rusch, VW ;
Rosenzweig, K ;
Venkatraman, E ;
Leon, L ;
Raben, A ;
Harrison, L ;
Bains, MS ;
Downey, RJ ;
Ginsberg, RJ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (04) :788-795
[30]   OPTIMAL MANAGEMENT OF MALIGNANT MESOTHELIOMA AFTER SUBTOTAL PLEURECTOMY - REVISITING THE ROLE OF INTRAPLEURAL CHEMOTHERAPY AND POSTOPERATIVE RADIATION [J].
SAUTER, ER ;
LANGER, C ;
COIA, LR ;
GOLDBERG, M ;
KELLER, SM .
JOURNAL OF SURGICAL ONCOLOGY, 1995, 60 (02) :100-105